<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898907</url>
  </required_header>
  <id_info>
    <org_study_id>ANG3777-HV5-104</org_study_id>
    <nct_id>NCT04898907</nct_id>
  </id_info>
  <brief_title>Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval</brief_title>
  <official_title>A Single Part, Four-Way Crossover, Randomized, Partially-Blinded Study to Evaluate the Effect of Intravenous ANG-3777 on Baseline-Adjusted QT/QTc Interval in the Fasted State in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angion Biomedica Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Angion Biomedica Corp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of ANG-3777 on placebo-corrected change&#xD;
      from baseline, QT/corrected QT (QTc) interval, following single intravenous (IV) doses in&#xD;
      healthy volunteer adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Partially blinded study. Patients are blinded as to treatment assignment. Care Provider, Investigator, and Outcomes Assessor will be blinded to ANG-3777 IV or saline IV, but Moxifloxacin Hydrochloride pill will be provided open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in corrected QT interval by Fridericia's formula for ANG-3777 at the therapeutic and supra-therapeutic dose levels compared to placebo</measure>
    <time_frame>Day 1, Day 5, Day 9 and Day 13</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>ANG-3777 (Therapeutic Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will be administered as a single dose on separate occasions intravenously as 30-minute infusions on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin Hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparator will be administered as a single dose oral Moxifloxacin Hydrochloride tablet (open-label), with a total of 240 mL of water. There will be a minimum washout of 3 days between each study drug administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANG-3777 (Supra-therapeutic Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANG-3777 (Therapeutic Dose)</intervention_name>
    <description>Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted</description>
    <arm_group_label>ANG-3777 (Therapeutic Dose)</arm_group_label>
    <other_name>Hepatocyte growth factor mimetic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANG-3777 (Supra-therapeutic Dose)</intervention_name>
    <description>Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted</description>
    <arm_group_label>ANG-3777 (Supra-therapeutic Dose)</arm_group_label>
    <other_name>Hepatocyte growth factor mimetic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Arms assigned to this intervention will receive normal saline, IV, Fasted</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Hydrochloride</intervention_name>
    <description>Arms assigned to this intervention will receive 400 mg, Oral, Fasted</description>
    <arm_group_label>Moxifloxacin Hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males or non-pregnant, non-lactating healthy females&#xD;
&#xD;
          2. Aged 18 to 55 years inclusive at the time of signing informed consent&#xD;
&#xD;
          3. Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening&#xD;
&#xD;
          4. Weight ≥50 kg and ≤100 kg at screening and admission&#xD;
&#xD;
          5. Must be willing and able to comply with all study requirements&#xD;
&#xD;
          6. Must be able to understand a written informed consent, which must be obtained prior to&#xD;
             initiation of study procedures&#xD;
&#xD;
          7. Must agree to use an adequate method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have received any IMP in a clinical research study within 5 half-lives or&#xD;
             within 30 days prior to first dose. However, in no event, shall the time between last&#xD;
             receipt of IMP and first dose be less than 30 days.&#xD;
&#xD;
          2. Subjects who are study site or sponsor employees, or are immediate family members of a&#xD;
             study site or sponsor employee&#xD;
&#xD;
          3. Evidence of current SARS-CoV-2 infection&#xD;
&#xD;
          4. History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          5. Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week&#xD;
             (1 unit = 12 oz 1 bottle/can of beer, 1 oz 40% spirit, or 5 oz glass of wine)&#xD;
&#xD;
          6. A confirmed positive alcohol urine test at screening or admission&#xD;
&#xD;
          7. Current smokers and those who have smoked within the last 12 months or current users&#xD;
             of e-cigarettes and nicotine replacement products and those who have used these&#xD;
             products within the last 12 months&#xD;
&#xD;
          8. A confirmed positive urine cotinine test at screening or admission.&#xD;
&#xD;
          9. Positive drugs of abuse test result&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Levy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences - Miami, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chantal Swiszcz</last_name>
    <phone>857-378-4175</phone>
    <email>cswiszcz@angion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Robledo</last_name>
    <phone>857-378-4173</phone>
    <email>mrobledo@angion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeffrey Levy, MD, PhD</last_name>
      <phone>305-644-9903</phone>
      <phone_ext>166</phone_ext>
      <email>jeffery.levy@quotientsciences.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

